BVCF
China's CARsgen raises $186m Series C
Chinese biotech player CARsgen Therapeutics has raised $186 million in Series C funding led by Loyal Valley Capital.
MicuRx Pharma gets $15m to support China drug trials
MicuRx Pharmaceuticals, a Sino-US bio-pharmaceutical company, has received RMB100 million ($15.1 million) in funding in a round led by existing investors Delian Capital and BVCF.
China's BVCF provides $8m round for US biotech firm
China-focused biotech investor BVCF has led an $8 million Series A round of funding for DiaCarta, a US-based firm that develops test kits for detecting cancer.
BVCF leads Series A for Shanghai immunotherapy firm
China-focused healthcare investor BVCF has led an undisclosed Series A round of funding for CARsgen, an immunotherapy firm that focuses on treating cancer.
BVCF-backed Jaguar Animal Health targets $54m US IPO
Jaguar Animal Health, a veterinary drugs developer backed by China-focused healthcare investor BVCF, is looking to raise as much as $54 million through a NASDAQ IPO.
China healthcare: Innovation issues
There is plenty of buzz about investment in Chinese healthcare but the pharmaceuticals segment has yet to fulfill its promise as an R&D hub. Should PE and VC investors be looking for different angles?
BVCF raises $200m for third China life sciences fund
BVCF, a China life sciences-focused PE firm, has reached a final close of $200 million on its third fund.
BVCF invests in US-based Jaguar Animal Health
China-focused BVCF has committed $2 million in a Series A round of funding for Jaguar Animal Health, a veterinary drugs developer, with another $3 million to come by the end of the month.
BVCF supports anti-viral drug innovation
Since the discovery of RNA interference (RNAi), a natural mechanism for regulating gene expression, in the 1990s, billions of dollars have been invested by the world’s pharmaceutical giants in using this technology to develop therapeutic drugs. A particular...